Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on March 27, 2026 - Change in KMP and SMP

Ceo ResignedCfo ResignedKmp ResignedManagement Changes View source PDF Explain this filing

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.1%Reaction day

₹379.20

prior close

₹371.40

announcement price

In-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-2.2%+0.1% vs market

Pharmaceuticals peers, median of 155sector-2.9%+0.8% vs sector

On the reaction day the stock moved 0.1 pts more than Nifty Midcap 150 and 0.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

+0.1

15m

-0.3

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.1-2.2+0.1-2.9+0.8

Next day

-5.1-4.7-0.3-4.7-0.3

-3.9-2.6-1.3-1.1-2.7

-7.2-2.9-4.3-0.7-6.5

-6.3-1.5-4.8+0.8-7.2

-10.3-1.4-8.9+1.4-11.7

-9.0+2.8-11.8+5.0-14.0

15d

-5.6+8.8-14.4+9.3-14.9

-4.6+8.8-13.4+10.8-15.4

+14.4+12.2+2.2+15.6-1.2

+9.2+11.2-2.0+18.4-9.2

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Biocon's board has approved a major leadership reshuffle effective April 1, 2026, as part of its plan to integrate Biocon Biologics into a single global biopharmaceutical company. CEO & Managing Director Siddharth Mittal and Interim CFO Mukesh Kamath have resigned from March 31, 2026 to move into other roles within the Biocon Group. Shreehas Pradeep Tambe, currently CEO of Biocon Biologics, will take over as the new CEO & MD for a 5-year term, subject to shareholder approval. Kedar Narayan Upadhye, CFO of Biocon Biologics, will become the new CFO. Additionally, 7 Senior Management Personnel have stepped down, and new CHRO, CTO, and Head of Governance, Risk & Compliance have been appointed, all internal transfers from Biocon Biologics.

Likely market impact

This is a planned, strategic leadership transition tied to the Biocon-Biocon Biologics integration announced in December 2025, rather than a sudden exit. Both outgoing and incoming leaders remain within the Biocon Group, which should limit disruption. The new CEO has a strong track record, having scaled Biocon Biologics into a top-5 global biosimilars player, which may be viewed positively by investors.